Hirneiss C, Neubauer A S, Niedermeier A, Messmer E M, Ulbig M, Kampik A
Department of Ophthalmology, Ludwig-Maximilians University, Muenchen, Germany.
Ophthalmology. 2006 Dec;113(12):2176-80. doi: 10.1016/j.ophtha.2006.05.060. Epub 2006 Sep 25.
Cost-utility and cost-effectiveness analyses are of increasing importance to clinicians and health policy experts. This study determines the costs in Germany and other countries in relation to gain of utility for patients with bilateral poor vision owing to corneal disease undergoing penetrating keratoplasty (PK) in 1 eye.
A cost-utility analysis was performed using retrospective clinical data and high-level evidence-based data.
Sixty patients (mean age, 46.3 years) with bilateral poor vision who underwent PK for corneal disease.
Visual acuity and utility values were obtained before and 1 year after PK and after suture removal. A 10-year graft survival rate of 80% was assumed. Expenses included costs for the corneal transplant and surgery, medication, and optical rehabilitation. A discount rate of 5% was applied for costs and quality-adjusted life years (QALYs). Cost-utility analysis encompassed a 10-year period after surgery.
The number of QALYs was calculated for the study group undergoing PK. This was divided into the cost of the procedure to get the number of euros spent per QALY gained.
Median binocular preoperative visual acuity was -log mean angle of resolution (-logMAR) 0.91+/-0.53 (Snellen equivalent 20/160) yielding a utility value of 0.67. After suture removal and optical rehabilitation, binocular visual acuity increased to median -logMAR 0.36+/-0.36 (20/46) with a utility value of 0.79. Over the 10 years after surgery and considering graft survival and discounting, a cost utility of 9551 euros per QALY was gained (equivalent to US11,557 dollars). One-way sensitivity analysis yielded a range from 7706 euros to 12874 euros per QALY, highlighting the robustness of the model.
Although an expensive procedure, PK is cost effective in patients with bilateral poor vision.
成本效用分析和成本效益分析对临床医生和卫生政策专家日益重要。本研究确定了德国和其他国家因角膜疾病导致双眼视力不佳且一只眼睛接受穿透性角膜移植术(PK)的患者在效用增益方面的成本。
使用回顾性临床数据和高级循证数据进行成本效用分析。
60例因角膜疾病接受PK的双眼视力不佳患者(平均年龄46.3岁)。
在PK前、PK后1年以及拆线后获取视力和效用值。假设移植10年生存率为80%。费用包括角膜移植和手术、药物治疗以及光学康复的成本。成本和质量调整生命年(QALY)采用5%的贴现率。成本效用分析涵盖手术后10年。
计算接受PK的研究组的QALY数量。将其除以手术成本以得出每获得一个QALY所花费的欧元数。
术前双眼视力中位数为-对数平均分辨角(-logMAR)0.91±0.53(Snellen等效值20/160),效用值为0.67。拆线和光学康复后,双眼视力中位数提高到-logMAR 0.36±0.36(20/46),效用值为0.79。在手术后的10年里,考虑到移植存活率和贴现,每QALY的成本效用为9551欧元(相当于11,557美元)。单向敏感性分析得出每QALY的范围为7706欧元至12,874欧元,突出了模型的稳健性。
尽管PK是一种昂贵的手术,但对于双眼视力不佳的患者具有成本效益。